S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Novel Findings from Clinical Studies Examining the Effects of Capesaris® (GTx-758) for the Treatment of Advanced Prostate Cancer to be Presented at 2013 American Society of Clinical Oncology Genitourinary Cancer Symposium (2013/2/13)|
|GTx Provides Corporate Update and Reports First Quarter 2013 Financial Results (2013/5/3)|
|GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review (2013/4/15)|
|GTx-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology Congress (2013/3/19)|
|GTx Provides Corporate Update and Reports 2012 Financial Results (2013/2/21)|
|GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer (2013/4/30)|
|GTx To Present Preclinical Data on a New Therapeutic Target in Prostate Cancer (2013/2/14)|
|Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet Oncology (2013/3/14)|
|GTx Announces Webcast of Corporate Presentation at 2013 Citi Global Healthcare Conference (2013/2/19)|
|GTx Announces Webcast of Corporate Presentation at Bio CEO & Investor Conference (2013/2/5)|
Click above to view more mutual fund data and stats for gtxi - GTx, Inc..